| Year |
Citation |
Score |
| 2017 |
Zuckerman JE, Moatamed NA. Sertoli-Leydig cell tumor of the ovary masquerading as a mucinous adenocarcinoma: a frozen section pitfall. Rare Tumors. 9: 6861. PMID 29081925 DOI: 10.4081/Rt.2017.6861 |
0.35 |
|
| 2017 |
Chaudhari S, Li W, Wang Y, Jiang H, Ma Y, Davis ME, Zuckerman JE, Ma R. STORE OPERATED CALCIUM ENTRY SUPPRESSED TGFβ1-SMAD3 SIGNALING PATHWAY IN GLOMERULAR MESANGIAL CELLS. American Journal of Physiology. Renal Physiology. ajprenal.00483.2016. PMID 28637791 DOI: 10.1152/Ajprenal.00483.2016 |
0.449 |
|
| 2017 |
Wu P, Ren Y, Ma Y, Wang Y, Jiang H, Chaudhari S, Davis ME, Zuckerman JE, Ma R. Negative regulation of Smad1 pathway and collagen IV expression by store-operated Ca2+ entry in glomerular mesangial cells. American Journal of Physiology. Renal Physiology. ajprenal.00642.2016. PMID 28298362 DOI: 10.1152/Ajprenal.00642.2016 |
0.459 |
|
| 2016 |
Clark AJ, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proceedings of the National Academy of Sciences of the United States of America. PMID 27001839 DOI: 10.1073/Pnas.1603018113 |
0.746 |
|
| 2015 |
Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nature Reviews. Drug Discovery. PMID 26567702 DOI: 10.1038/Nrd4685 |
0.517 |
|
| 2015 |
Wu P, Wang Y, Davis ME, Zuckerman JE, Chaudhari S, Begg M, Ma R. Store-Operated Ca2+ Channels in Mesangial Cells Inhibit Matrix Protein Expression. Journal of the American Society of Nephrology : Jasn. PMID 25788524 DOI: 10.1681/Asn.2014090853 |
0.435 |
|
| 2015 |
Zuckerman JE, Gale A, Wu P, Ma R, Davis ME. siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Therapeutics. 25: 53-64. PMID 25734248 DOI: 10.1089/Nat.2014.0505 |
0.636 |
|
| 2015 |
Clark A, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME, Eliasof S. Abstract B33: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B33 |
0.752 |
|
| 2014 |
Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proceedings of the National Academy of Sciences of the United States of America. 111: 11449-54. PMID 25049380 DOI: 10.1073/Pnas.1411393111 |
0.784 |
|
| 2013 |
Zuckerman JE, Davis ME. Targeting therapeutics to the glomerulus with nanoparticles. Advances in Chronic Kidney Disease. 20: 500-7. PMID 24206602 DOI: 10.1053/J.Ackd.2013.06.003 |
0.633 |
|
| 2013 |
Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, Schluep T, Chao J, Lin J, Yen Y, Han H, Wiley DT, Zuckerman JE, Davis ME. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proceedings of the National Academy of Sciences of the United States of America. 110: 15127-32. PMID 23980155 DOI: 10.1073/Pnas.1309566110 |
0.738 |
|
| 2012 |
Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM. Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. Journal of Controlled Release : Official Journal of the Controlled Release Society. 159: 384-92. PMID 22342644 DOI: 10.1016/J.Jconrel.2012.01.045 |
0.717 |
|
| 2012 |
Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proceedings of the National Academy of Sciences of the United States of America. 109: 3137-42. PMID 22315430 DOI: 10.1073/Pnas.1200718109 |
0.706 |
|
| 2012 |
Collisson EA, Zuckerman J, Wang D, Phojanakong P, Gale AB, Choi CHJ, Hann B, McCormick F, Davis M. Abstract 2906: Preclinical systems to study the biodistribution of nanoparticle delivery in pancreatic ductal adenocarcinoma Cancer Research. 72: 2906-2906. DOI: 10.1158/1538-7445.Am2012-2906 |
0.436 |
|
| 2011 |
Choi CH, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proceedings of the National Academy of Sciences of the United States of America. 108: 6656-61. PMID 21464325 DOI: 10.1073/Pnas.1103573108 |
0.713 |
|
| 2011 |
Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. The Journal of Investigative Dermatology. 131: 453-60. PMID 20944646 DOI: 10.1038/Jid.2010.310 |
0.474 |
|
| 2011 |
Zuckerman JE, Han H, Medrano L, Choi CHJ, Davis ME. Abstract C134: Herceptin-targeted siRNA nanoparticles inhibit the growth Her2-positive breast cancer tumors in vivo. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C134 |
0.648 |
|
| 2011 |
Zuckerman JE, Ribas A, Davis ME. Reply to Perris, Borghese, and Magro Pigment Cell and Melanoma Research. 24: 983-985. DOI: 10.1111/J.1755-148X.2011.00897.X |
0.448 |
|
| 2010 |
Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 464: 1067-70. PMID 20305636 DOI: 10.1038/Nature08956 |
0.752 |
|
| 2010 |
Ribas A, Kalinoski L, Heidel JD, Peterkin J, Seligson DB, Zuckerman JE, Choi C, Yen Y, Davis ME, Tolcher AW. Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial. Journal of Clinical Oncology. 28: 3022-3022. DOI: 10.1200/Jco.2010.28.15_Suppl.3022 |
0.778 |
|
| Show low-probability matches. |